- 1.
Powell LW, Leggett BA, Crawford DHG. Hemochromatosis and other iron storage disorders. I: Schiff ER, Sorrell MF, Maddrey WC, red. Schiff’s Diseases of the liver. Philadelphia: Lippincott-Raven, 1999: 1107 – 30.
- 2.
Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399 – 408.
- 3.
Bell H, Thordal C, Raknerud N, Hansen T, Bosnes V, Halvorsen R et al. Prevalence of hemochromatosis among first-time and repeat blood donors in Norway. J Hepatol 1997; 26: 272 – 9.
- 4.
Gutteridge JMC. Free radicals in disease processes: a compilation of cause and consequence. Free Rad Res Commun 1993; 19: 141 – 58.
- 5.
McCord JM. Effects of positive iron status at a cellular level. Nutr Rev 1996; 54: 85 – 8.
- 6.
Marx JJM, van Asbeck BS. Use of chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta Haematol 1996; 95: 49 – 62.
- 7.
Yuan XM, Brunk UT. Iron and LDL-oxidation in atherogenesis. APMIS 1998; 106: 825 – 42.
- 8.
de Valk B, Marx JJM. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999; 159: 1542 – 8.
- 9.
Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997; 96: 3300 – 7.
- 10.
Roest M, van der SchouwYT, de Valk B, Marx JJM, Tempelman MJ, de Groot PG et al. Heterozygosity for hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999; 100: 1268 – 73.
- 11.
Tuomainen T-P, Kontula K, Nyyssönen K, Lakka TA, Heliö T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation. A prospective cohort study in men in eastern Finland. Circulation 1999; 100: 1274 – 9.
- 12.
Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077 – 84.
- 13.
Lund EK, Wharf SG, Fairweather-Tait SJ, Johnson IT. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr 1999; 69: 250 – 5.
- 14.
Kato I, Dnistrian AM, Schwartz M, Toniolo P, Koenig K, Shore RE et al. Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study. Int J Cancer 1999; 80: 693 – 8.
- 15.
Biasi D, Carletto A, Caramaschi P, Maleknia T, Scambi C, Melchiori S et al. The articular damage of hemochromatosis. A little known aspect. Recenti Prog Med 1999; 90: 226 – 30.
- 16.
Smith MD, Pannacciulli IM. Absorption of inorganic iron from graded doses. Br J Haematol 1958; 4: 428 – 34.
- 17.
Bell H, Berg JP, Undlien DE, Distante S, Raknerud N, Heier HE et al. The clinical expression of hemochromatosis in Oslo, Norway. Excessive oral iron intake may lead to secondary hemochromatosis even in HFE C282Y mutation negative subjects. Scand J Gastroenterol 2000; 35: 1301 – 7.
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.